

# Role of Mitochondrial Dynamics in Microglial Activation and Metabolic Switch

**Alejandro Montilla**

University of the Basque Country

**Asier Ruiz**

University of the Basque Country

**Mar Marquez**

University of the Basque Country

**Amanda Sierra**

University of the Basque Country

**Carlos Matute**

University of the Basque Country

**Maria Domercq** (✉ [maria.domercq@ehu.es](mailto:maria.domercq@ehu.es))

University of the Basque Country

---

## Research Article

**Keywords:** microglia, metabolic switch, pro-inflammatory stimuli, Mdivi-1, mitochondria

**Posted Date:** January 6th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-134161/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 **Role of mitochondrial dynamics in microglial activation and metabolic**  
2 **switch**

3 **Alejandro Montilla<sup>1,2</sup>, Asier Ruiz<sup>1,2</sup>, Mar Marquez<sup>1</sup>, Amanda Sierra<sup>1,3</sup>, Carlos**  
4 **Matute<sup>1,2</sup> and Maria Domercq<sup>1,2\*</sup>**

5 1- Achucarro Basque Center for Neuroscience and Department of Neuroscience,  
6 University of the Basque Country UPV/EHU, E-48940 Leioa, Spain

7 2- Centro de Investigación Biomédica en Red de Enfermedades  
8 Neurodegenerativas (CIBERNED), Leioa, Spain.

9 3- Ikerbasque Foundation, E-48009, Bilbao, Spain

10 **\*Correspondence should be addressed to:** María Domercq, Dpto. Neurociencias,  
11 Universidad del País Vasco, E-48940 Leioa, Spain. Tel: +34-94-6015681. Fax: +34-94-  
12 6015055. E-mail: [maria.domercq@ehu.es](mailto:maria.domercq@ehu.es)

13

14 **ABSTRACT**

15 Microglia act as sensors of injury in the brain, favouring its homeostasis. Their activation  
16 and polarization towards a pro-inflammatory phenotype are associated to injury and  
17 disease. These processes are linked to a metabolic reprogramming of the cells,  
18 characterized by high rates of glycolysis and suppressed oxidative phosphorylation. This  
19 metabolic switch can be reproduced *in vitro* by microglial stimulation with  
20 lipopolysaccharide (LPS) plus interferon- $\gamma$  (IFN $\gamma$ ). In order to understand the  
21 mechanisms regulating mitochondrial respiration abolishment, we examined potential  
22 alterations in mitochondrial features during this switch. Cells did not show any change in  
23 mitochondrial membrane potential, suggesting a limited impact in the mitochondrial  
24 viability. We provide evidence that reverse operation of F<sub>0</sub>F<sub>1</sub>-ATP synthase contributes  
25 to mitochondrial membrane potential. In addition, we studied the possible implication of  
26 mitochondrial dynamics in the metabolic switch using the mitochondrial division  
27 inhibitor-1 (Mdivi-1), which blocks Drp1-dependent mitochondrial fission. Mdivi-1  
28 significantly reduced the expression of pro-inflammatory markers in LPS+IFN $\gamma$ -treated  
29 microglia. However, this inhibition did not lead to a recovery of the oxidative  
30 phosphorylation ablation by LPS+IFN $\gamma$  or to a microglia repolarization. Altogether, these  
31 results suggest that Drp1-dependent mitochondrial fission, although potentially involved  
32 in microglial activation, does not play an essential role in metabolic reprogramming and  
33 repolarization of microglia.

34 **Keywords:** microglia, metabolic switch, pro-inflammatory stimuli, Mdivi-1,  
35 mitochondria

## 36 INTRODUCTION

37 Microglial cells are the resident macrophages of the central nervous system (CNS). They  
38 contribute to the tissue development, integrity and homeostasis through an active  
39 surveillance process <sup>1,2</sup> that can lead to different states of activation. Microglia display an  
40 enormous plasticity of responses to injury, ranging from effects that may contribute to  
41 neuroinflammation and eventually tissue damage, to essential responses for regenerative  
42 processes <sup>3</sup>. These mechanisms are associated to a broad spectrum of activation states,  
43 which are in turn related to molecular changes and adaptations <sup>4</sup>. One of these adaptive  
44 mechanisms is the metabolic reprogramming of microglia and other immune cells in  
45 response to immune activation <sup>5-8</sup>. Similar to macrophages <sup>6,7</sup>, microglia exposed to pro-  
46 inflammatory stimulus shift their metabolism from oxidative phosphorylation  
47 (OXPHOS) to aerobic glycolysis <sup>9,10</sup>, in an event similar to the Warburg effect suffered  
48 by cancer cells <sup>7</sup>. This metabolic reprogramming is essential to activate cellular defense  
49 mechanisms and to manage various microenvironments in inflamed tissue <sup>7,11-13</sup>.  
50 Moreover, these cells overexpress inflammatory markers such as interleukin-1 $\beta$  (IL-1 $\beta$ ),  
51 tumour necrotic factor  $\alpha$  (TNF $\alpha$ ), or inducible nitric oxide synthase (iNOS), which takes  
52 part in the metabolism of arginine. In contrast, macrophages exposed to anti-  
53 inflammatory stimuli are primarily characterized by oxidative phosphorylation and  
54 increased fatty acid oxidation for ATP synthesis <sup>6,12</sup>, a fact that has not been corroborated  
55 in microglia cells. This anti-inflammatory activation is commonly accompanied by an  
56 increase in the expression of specific markers, such as arginase 1 (Arg1), which competes  
57 with iNOS to hydrolyse arginine to ornithine <sup>14</sup>, or the mannose receptor (MNR).

58 As mitochondria are crucial organelles in OXPHOS-related metabolism of the cells, we  
59 hypothesized that disbalances in their integrity or dynamics, may contribute to microglia  
60 metabolic reprogramming towards a glycolytic phenotype. Mitochondrial dynamics,

61 involving processes of both fusion and fission, are known to contribute to cell  
62 homeostasis and the maintenance of other mitochondrial functions <sup>15</sup>. Basal  
63 mitochondrial fission is required for mitochondrial trafficking to synapses, mitochondrial  
64 quality control, and brain development <sup>16</sup>. Misbalances in these dynamic mechanisms are  
65 thought to contribute to the development of various neurological disorders <sup>17-19</sup>.  
66 Moreover, these processes are associated to the production of reactive oxygen species  
67 (ROS). Mitochondrial fission is triggered by the dynamin-related protein 1 (Drp-1)  
68 recruitment from the cytosol to the outer mitochondrial membrane, which is mediated by  
69 different adaptor proteins <sup>20,21</sup>. Lately, the pharmacological inhibition of Drp1 with the  
70 mitochondrial division inhibitor 1 (Mdivi-1), a quinazolinone derivative, has become a  
71 promising strategy to analyse the physiological and pathological role of mitochondrial  
72 fission <sup>22</sup>.

73 We tested whether mitochondria are functionally affected during metabolic  
74 reprogramming conditions. Moreover, we assessed whether mitochondrial fission is  
75 involved in microglia metabolic reprogramming. We used Mdivi-1 to block Drp1-  
76 dependent mitochondrial fission *in vitro*, and found that whereas this inhibition leads to  
77 a modulation of the expression of inflammatory markers in microglial cells, this is not  
78 sufficient to alter the metabolic switch suffered by the cells, in sharp contrast with the  
79 results reported in a previous study <sup>9</sup>. Furthermore, as Mdivi-1 treatment generated a  
80 decrease in iNOS expression, we have assessed whether this outcome was capable to  
81 favour a repolarization process in microglia.

## 82 **MATERIALS AND METHODS**

### 83 **Animals**

84 All experiments were performed according to the procedures approved by the Ethics  
85 Committee of the University of the Basque Country (UPV/EHU). Animals were handled  
86 in accordance with the European Communities Council Directive, and were kept under  
87 conventional housing conditions ( $22 \pm 2^\circ\text{C}$ ,  $55 \pm 10\%$  humidity, and 12-h day/night cycle)  
88 at the UPV/EHU animal facilities. The study was carried out in compliance with the  
89 ARRIVE guidelines. All possible efforts were made to minimize animal suffering and the  
90 number of animals used.

### 91 **Microglial culture**

92 Primary mixed glial cultures were prepared from the cerebral cortex of neonatal rats (P0-  
93 P2). After 10-15 days in culture, microglia were isolated by mechanical shaking (400  
94 rpm, 1h) and purified by plating them on non-coated bacterial grade Petri dishes (Sterilin;  
95 Thermo Fisher), as previously described<sup>23</sup>. Microglial cells obtained with this procedure  
96 were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco) supplemented  
97 with 10% Fetal Bovine Serum (FBS; Gibco).

98 Microglial cells were polarized with specific stimuli. To generate an anti-inflammatory  
99 phenotype in these cells, they were treated for 24 hours with IL-4 (20 ng/ml; Peprotech)  
100 and IL-13 (50 ng/ml; Peprotech). On the other hand, pro-inflammatory microglia were  
101 generated with a treatment of both LPS (10 ng/mL; Sigma-Aldrich) and IFN $\gamma$  (20 ng/ml;  
102 Peprotech) 24 hours. In the experiments for the study of the pro-inflammatory activation  
103 time course, the LPS+IFN $\gamma$  treatment was maintained for 2, 6 or 24 hours. The  
104 repolarization protocol implied a 24h pro-inflammatory activation followed by the  
105 treatment with the anti-inflammatory stimuli for the same amount of time.

## 106 **Immunofluorescence analysis**

107 Several immunocytochemistry (ICC) assays were performed on the cells in different  
108 conditions. Cells in culture were fixed in 4% p-formaldehyde (PFA) in PBS and processed  
109 for ICC as previously described <sup>24</sup>. Primary antibodies were used as follows to: Iba1  
110 (1:500, Wako), iNOS (1:500, BD Bioscience), a pro-inflammatory marker, and mannose  
111 receptor C type 1 (MRC1; 1:1000, Abcam), specific for anti-inflammatory cells. As  
112 secondary antibodies, we used goat anti-rabbit Alexa Fluor 488 (1:250 Invitrogen) and  
113 goat anti-mouse Alexa Fluor 594 (1:250, Invitrogen). The morphology of microglial cells  
114 was analyzed using the Iba1 immunofluorescence, as the whole soma was stained by it.  
115 The circularity of the cell was calculated as defined in the ImageJ software; a circular  
116 shape would approach a value of 1. All the image analysis was performed with the ImageJ  
117 software (NIH). Immunoreactivity of the different markers was calculated as the  
118 fluorescence intensity normalized to the number of cells in the selected field of view.

## 119 **Cell viability assays**

120 Microglial viability was assessed using both the calcein-AM dye (Invitrogen) and the  
121 Cytotox 96® Non-Radioactive Cytotoxicity Assay (Promega).

122 For the performance of the calcein assay, cells were incubated with 0.5 µM of the dye for  
123 30 minutes at 37° C. The wells were then washed with PBS and the number of viable cells  
124 were calculated with a Synergy HT fluorimeter/spectrophotometer reader (Bio-Tek) with  
125 485 nm excitation and at 528 nm of emission wavelengths. A well with PBS was also  
126 measured in each experiment to subtract its values as a background control. The results  
127 are expressed as the relative percentage of cellular death with respect to non-treated  
128 microglial cells.

129 For the Cytotox 96® Non-Radioactive Cytotoxicity Assay, culture supernatants were  
130 harvested from the plate, mixed with the specific Assay Buffer and incubated for 30  
131 minutes at 37° C. The reaction was then stopped and the absorbance at 490 nm was  
132 immediately recorded in the fluorimeter. The levels of absorbance are associated with the  
133 amount of lactate dehydrogenase in the medium, a stable cytosolic enzyme that is released  
134 upon cellular death and its consequent lysis. All the data obtained through both assays  
135 was analysed using Gen5 software (Bio-Tek).

### 136 **Quantitative RT-PCR**

137 Total RNA of microglial cells was extracted using Trizol (Invitrogen) according to the  
138 manufacturer's instructions. Afterwards, 1 µg of this RNA was used to perform a  
139 retrotranscription protocol, using SuperScript III retrotranscriptase (200 U/µl; Invitrogen)  
140 and random hexamers as primers (Promega).

141 Real-time quantitative PCR reactions (qPCRs) were conducted in a Bio-Rad CFX96 real-  
142 time PCR detection system, as previously described <sup>25</sup>. The reactions were performed  
143 using SYBR-Green as a DNA-binding dye, and specific primers for anti-inflammatory  
144 and pro-inflammatory markers (Table 1). These primers were designed using Primer  
145 Express software (Applied Biosystems) at exon junctions to avoid genomic DNA  
146 amplification. The cycling conditions comprised 3 minutes of polymerase activation at  
147 95°C and 40 cycles consisting of 10 seconds at 95°C and 30 seconds at 60°C. After every  
148 qPCR reaction, the melting curve was assessed in order to check the specificity of the  
149 amplification. The amount of cDNA was quantified using a standard curve from a pool  
150 of cDNA obtained from the different conditions of each experiment. Subsequently, the  
151 results were normalized using a normalization factor, based on the geometric mean of  
152 housekeeping genes (Table 1), obtained for each condition using the GeNorm v3.5  
153 software <sup>26</sup>.

## 154 **Mitochondrial membrane potential and mitochondrial calcium measurements**

155 For quantification of mitochondrial membrane potential, microglial cells were loaded  
156 with quenching concentrations of Rhodamine 123 (Rh123; 10  $\mu$ M) for 20 min in medium  
157 without phenol red. After this, microglia were washed for 10 minutes in the same medium.  
158 Living cell imaging was performed with a 63x objective in an inverted Leica LCS SP2-  
159 AOBS confocal microscope at an acquisition rate of 1 frame every 15 seconds for 5 min.  
160 After obtaining some basal images, FCCP (1  $\mu$ M), an uncoupler of the mitochondrial  
161 oxidative phosphorylation, was added to the plates and the increase in the Rh123  
162 fluorescence level was measured to determine the membrane potential. For each plate, a  
163 homogenous population of approximately 20 cells was selected in the field of view, and  
164 the background fluorescence signal was subtracted from the individual values.

165 For the measurement of the mitochondrial calcium content time-lapse images were  
166 acquired using a 63X objective in a Leica TCS STED CW SP8 confocal microscope, at  
167 an acquisition rate of 1 frame every 15 seconds for 5 min. Cells were loaded with 1  $\mu$ M  
168 Fluo-4 (Thermo Fisher) in HBSS ( $\text{Ca}^{2+}$ - and  $\text{Mg}^{2+}$ -free) with 0.5  $\mu$ M EGTA for 30  
169 minutes at 37°C. Subsequently, microglial cells were washed and after obtaining some  
170 basal images, 1  $\mu$ M FCCP was added to depolarize the mitochondrial membrane and force  
171 the release of  $\text{Ca}^{2+}$  from mitochondrial matrix to the cytosol. The analysis was made as  
172 above.

## 173 **Mitochondrial morphology analysis**

174 For the quantification of mitochondrial length, living cell imaging was performed on  
175 microglial cells, loaded with Rhodamine 123 (Rh123; 50 nM) for 20 min. Mitochondrial  
176 images were taken using a Zeiss LSM800 confocal microscope at 40X magnification and  
177 a pixel resolution of 1024x1024, and analyzed using the Object Analyzer tool of Huygens

178 image analysis software (Scientific Volume Imaging, B.V, version 20.10). First,  
179 background noise was removed using the maximum fluorescence intensity value of  
180 Rhodamine 123 in the nuclear region. Afterwards, a size filter was applied to remove  
181 objects smaller than mitochondria ( $38 \text{ voxels} = 0.06 \mu\text{m}^3$ )<sup>27</sup>. Next, a watershed  
182 segmentation was performed using a Sigma value of 0.2 to separate objects that were not  
183 discriminated in the raw images due to the inherent resolution limit of confocal  
184 microscopy. After this pre-processing, the average length of each mitochondrial object  
185 per cell was calculated.

### 186 **Oxygen consumption rate analysis**

187 Real time measurements of oxygen consumption rate (OCR), extracellular acidification  
188 rate (ECAR) and glycolytic proton efflux rate (glycoPER) were performed using a  
189 Seahorse XFe96 Extracellular Flux Analyzer (Agilent), following manufacturer's  
190 instructions to carry out the XF Cell Mito Stress Test Kit or the XF Glycolytic Rate Assay  
191 Kit (Agilent). Microglia cells were seeded as a monolayer in the XF96 microplate. Before  
192 the assay, cells were washed and equilibrated in the XF Assay modified DMEM medium  
193 for 30 minutes at 37°C.

194 For the performance of the XF Cell Mito Stress Test Kit, the real levels of OCR were  
195 determined in response to the sequential addition of oligomycin ( $2 \mu\text{M}$ ), FCCP ( $1 \mu\text{M}$ )  
196 and rotenone/antimycin A ( $0.5 \mu\text{M}$ ). Specifically, basal mitochondrial respiration was  
197 calculated subtracting OCR rate after rotenone/antimycin A addition from basal OCR. as  
198 the last measurement before addition of oligomycin – non-mitochondrial respiration  
199 (minimum rate measurement after the treatment with rot/antA). The spare respiratory  
200 capacity was obtained by subtracting the basal respiration level from the maximum rate

201 measurement after addition of FCCP. ATP-linked OCR was determined by subtracting  
202 oligomycin-induced OCR from basal OCR.

203 For the measurement of the basal glycoPER, the XF Glycolytic Rate Assay Kit was  
204 carried out. This test includes the sequential addition of rotenone/antimycin A (0.5  $\mu$ M),  
205 and 2-deoxyglucose (2-DG; 50 mM). The glycoPER corresponds to the proton efflux rate  
206 derived from glycolysis (discounting the effect of CO<sub>2</sub>-dependent acidification, included  
207 in the ECAR measurement) All these parameters were obtained using the specific Agilent  
208 Report Generator. For each single experiment, eight replicates were performed.

## 209 **Data analysis**

210 All the data shown in the figures are presented as the mean  $\pm$  SEM. All the statistical  
211 analyses were performed with GraphPad Prism 8.0 (GraphPad Software, Inc.).  
212 Specifically, every comparison between two groups was analysed using paired Student's  
213 two-tailed t-test. Comparison among multiple groups were analysed by one-way analysis  
214 of variance (ANOVA) followed by Bonferroni's multiple comparison tests for *post hoc*  
215 analysis. Statistical significance was considered at  $p < 0.05$ .

## 216 RESULTS

### 217 Metabolic reprogramming in microglia is not associated to mitochondrial damage

218 To test whether microglia metabolic reprogramming from OXPHOS to glycolysis upon  
219 pro-inflammatory stimulation is associated to mitochondrial damage, we set up an *in vitro*  
220 protocol to study the metabolic switch and we measured oxygen consumption rate (OCR)  
221 and extracellular acidification rate (ECAR) in real time as indicative of mitochondrial  
222 respiration and glycolysis respectively. Cells treated with classical pro-inflammatory  
223 stimuli (LPS and IFN $\gamma$ ) showed a flat profile regarding OXPHOS, and all the parameters  
224 (basal OCR, ATP-linked respiration and spare respiratory capacity) related to this  
225 molecular process were practically abolished (Fig. 1A), as previously described<sup>28</sup>. This  
226 suggests a metabolism shift from OXPHOS to glycolysis in order to rapidly obtain  
227 energy. Conversely, microglia treated with anti-inflammatory factors (IL-4 and IL-13)  
228 showed a significant increase in basal OCR, spare respiratory capacity and ATP-linked  
229 respiration, thus, indicating that mitochondrial OXPHOS was boosted. In contrast, ECAR  
230 measurement showed an increase in basal glycolysis in both pro-inflammatory and anti-  
231 inflammatory microglia (Fig. 1B), suggesting that activated microglia have higher  
232 energetic demands. Moreover, inhibition of mitochondrial F<sub>0</sub>F<sub>1</sub>-ATP synthase with  
233 oligomycin, thus blocking OXPHOS, increased glycolytic rate in control and anti-  
234 inflammatory microglia but not in pro-inflammatory microglia (Fig. 1B). Finally, the  
235 basal ratio between mitochondria OCR (mitoOCR) and the glycolytic proton efflux rate  
236 (glycoPER) was significantly inhibited in pro-inflammatory microglia (Fig. 1C). These  
237 results further support the idea that pro-inflammatory microglia metabolism relies  
238 exclusively on glycolysis.

239 In other immune cells, such as dendritic cells, the metabolic switch to glycolysis occurs  
240 within minutes after TLR activation with LPS<sup>29</sup>. However, microglia acute treatment

241 with LPS did not induce any change in OCR (Fig. 1D). Time course analysis  
242 demonstrated that the metabolic switch began to occur at 2h, was clear at 6h and  
243 completed at 24h (Fig. 1E).

244 Since OXPHOS takes place in the mitochondrial inner membrane and it is determinant  
245 for H<sup>+</sup> movement and mitochondrial membrane potential ( $\Delta\Psi_m$ ) maintenance, the arrest  
246 of mitochondrial OXPHOS by pro-inflammatory stimuli could induce a collapse in  $\Delta\Psi_m$ .

247 To check whether mitochondrial membrane potential was altered in microglia treated  
248 with pro-inflammatory stimuli, we performed live cell imaging of Rhodamine 123  
249 (Rh123) fluorescent dye in microglia under “quenching” conditions<sup>30</sup>. Addition of the  
250 mitochondrial oxidative phosphorylation uncoupler FCCP provoked the release of Rh123  
251 from the mitochondria and consequently increased its cytoplasmic fluorescence two-fold  
252 over baseline (100%) in control microglia as well as in microglia treated with LPS + IFN $\gamma$   
253 (Fig. 2A), indicating that basal mitochondrial potential is maintained in pro-inflammatory  
254 microglia despite the arrest of OXPHOS. To further assess mitochondrial integrity we  
255 measured resting  $[Ca^{2+}]_{mit}$  by recording  $[Ca^{2+}]_{cyt}$  upon addition of FCCP in the absence  
256 of extracellular Ca<sup>2+</sup>, which is indicative for  $[Ca^{2+}]_{mit}$ <sup>31</sup>. Again, we observed no  
257 significant differences in the release of mitochondrial calcium to the cytosol after the  
258 addition of FCCP (Fig. 2B). Moreover, pro-inflammatory stimulation of microglia  
259 induced a significant increase in reactive oxygen species (ROS) production, as revealed  
260 with the dichlorofluorescein diacetate (DCFDA) dye (Fig. 2C), despite the blockage of  
261 OXPHOS. All these results suggest that pro-inflammatory activation and its subsequent  
262 lack of OXPHOS activity in microglia is not related to and it does induce any  
263 mitochondrial dysfunction or alteration in mitochondrial membrane potential.

264 Maintaining mitochondrial membrane potential is essential to prevent the release of pro-  
265 apoptotic factors into the cytosol and subsequent cell death. Indeed, despite the blockage

266 of OXPHOS, LPS plus IFN $\gamma$  stimulation did not induce any significant microglia cell  
267 death (Fig. 2D). We hypothesized that  $\Delta\Psi_m$  could be maintained in cells with respiration  
268 inhibited by the reverse operation of F<sub>0</sub>F<sub>1</sub>-ATP synthase and the adenine nucleotide  
269 translocase (ANT), which pump H<sup>+</sup> out of the matrix <sup>32</sup>. To test this hypothesis, we  
270 analysed the impact of the F<sub>0</sub>F<sub>1</sub>-ATP synthase and ANT in cell viability and  $\Delta\Psi_m$ . Indeed,  
271 treatment of LPS + IFN $\gamma$  stimulated microglia with oligomycin, a F<sub>0</sub>F<sub>1</sub>-ATP synthase  
272 inhibitor, induced a significant increase in microglia cell death (Fig. 2D). In contrast,  
273 bongkrekic acid, an inhibitor of ANT <sup>33</sup>, did not induce microglia cell death (Fig. 2D).  
274 Accordingly, a role of F<sub>0</sub>F<sub>1</sub>-ATP synthase in mitochondrial  $\Delta\Psi_m$  maintenance in pro-  
275 inflammatory microglia was further corroborated by live cell imaging of  
276 tetramethylrhodamine ethyl ester (TMRE), a fluorescent dye that accumulates in active  
277 mitochondria. Addition of oligomycin induced a significant decrease in  $\Delta\Psi_m$  in pro-  
278 inflammatory microglia but not in control microglia (Fig. 2E), supporting the idea that  
279 the former's mitochondrial integrity depends on the activity of the ATP synthase.

## 280 **Mitochondrial fission inhibition does not reverse mitochondrial metabolic** 281 **reprogramming**

282 Previous data have showed that activation of microglia with LPS induced a transient  
283 shortening of mitochondria by fission at 2h. Similarly, we detected a shortening of  
284 mitochondrial length at 2h after LPS + IFN $\gamma$  treatment, an effect that was reverted in the  
285 presence of the mitochondrial fission inhibitor Mdivi-1 <sup>9,34</sup> (Figure S1). Since microglia  
286 metabolic switch has been associated previously to mitochondrial fission <sup>9</sup>, we further  
287 analysed this hypothesis in our cultures using Mdivi-1. First, we assessed whether the  
288 Mdivi-1 treatment would have an effect on microglia itself. A 24h-treatment with Mdivi-

289 1 (50  $\mu$ M) provoked a morphological change in microglia with a significant increase in  
290 cytoplasm circularity, indicating that Mdivi-1 treatment induces an amoeboid  
291 morphology (Fig. 3A). Although this characteristic is generally associated with cell  
292 activation, we found no differences in the basal expression of pro-inflammatory (iNOS)  
293 or anti-inflammatory markers (mannose receptor, MNR) (Fig. 3B), nor in cell viability  
294 (Fig. 3C). However, Mdivi-1 reduced significantly the increased expression of iNOS in  
295 response to LPS and IFN $\gamma$  stimulation (Fig. 3D). We further analysed by qPCR the  
296 expression of different pro-inflammatory mediators. Treating microglia with LPS + IFN-  
297  $\gamma$  induced an increase in all the pro-inflammatory genes expression assessed (*Ccl2*, *Il1b*,  
298 *iNOS*) with respect to control cells, and also the expression of arginase-1 (*Arg1*), an anti-  
299 inflammatory mediator which is known to carry an opposite function to iNOS regarding  
300 cellular metabolism<sup>14</sup>. The treatment with Mdivi-1 significantly reduced pro-  
301 inflammatory mediators overexpression as well as that of Arg1 (Fig. 3E). These results  
302 suggest that Drp1-dependent mitochondrial fission is potentially involved in microglial  
303 activation.

304 Next, we checked whether the impact of Mdivi-1 on microglial activation could affect  
305 microglia metabolic reprogramming. In addition to the blockage of drp-1 mitochondrial  
306 fission, Mdivi-1 could inhibit acutely and reversibly mitochondrial complex I in neurons  
307<sup>35</sup>. To determine the direct impact of Mdivi-1 on microglial bioenergetics, we treated  
308 microglia with Mdivi-1 for 1h and 24h and we measured microglial OCR. We also  
309 observed a reduction in mitochondrial respiration at 1h, however the effect was transient  
310 and disappeared at 24h (Fig. 4A, B). Next, we analysed the impact of Mdivi-1 on the  
311 metabolic switch of pro-inflammatory microglia. Treatment with Mdivi-1 did not  
312 increase OCR levels in cells stimulated with LPS and IFN $\gamma$ , to recover the normal  
313 bioenergetics profile (Fig. 4B). These results indicate that, although Drp1-mediated

314 mitochondrial fission could modulate or contribute to microglia activation, it does not  
315 play an active role in the metabolic switch produced in inflammatory paradigms.

### 316 **Mdivi-1 treatment does not improve microglial repolarization**

317 Redirection of microglia from a detrimental to a regenerative phenotype is a major  
318 concept to develop new therapies targeting these cells <sup>36</sup>. Nitric oxide (NO), the product  
319 of iNOS activity, blunts mitochondrial respiration of pro-inflammatory macrophages and  
320 this dysfunction prevents editing macrophage towards an anti-inflammatory phenotype.  
321 Thus, inhibiting NO production improves mitochondrial metabolic impairment and  
322 macrophages reprogramming towards an anti-inflammatory phenotype <sup>37</sup>. Given that  
323 Mdivi-1 reduced iNOS expression in pro-inflammatory microglia, we assessed the  
324 capacity of Mdivi-1 to promote repolarization in microglia. To that end, microglia cells  
325 were primed for 24 hours with LPS+IFN $\gamma$  (with or without Mdivi-1, to reduce NO  
326 production), and then treated 24h with anti-inflammatory cytokines (see scheme on Fig.  
327 5A). We first compared the IL-4+IL-13-induced response in cells previously primed with  
328 LPS+IFN $\gamma$  with the response of cells exposed to anti-inflammatory stimulus only. After  
329 exposure to IL-4+IL-13, microglia primed with LPS+IFN $\gamma$  exhibited efficient  
330 upregulation in the expression of the anti-inflammatory marker mannose receptor and  
331 downregulation in the expression of iNOS (Fig. 5B). The expression of iNOS and MNR  
332 were further reduced or increased respectively in cells treated with Mdivi-1 during  
333 LPS+IFN $\gamma$  priming (Fig. 5B). When the metabolic profile of the cells was assessed using  
334 Seahorse XFe96 Analyzer, we observed that microglia primed with LPS+IFN $\gamma$  recovered  
335 partially the mitochondrial respiration after exposure to IL-4+IL-13. However, Mdivi-1  
336 treatment during LPS+IFN $\gamma$  priming did not further enhance the final OCR and therefore

337 the OXPHOS activity (Fig. 5C). These results do not support the implication of  
338 mitochondrial dynamics in the repolarization process of microglia.

## 339 **DISCUSSION**

340 Immunometabolism has recently emerged as an important focus of research, as it opens  
341 a novel therapeutic approach for inflammatory and autoimmune diseases. To conduct  
342 some responses, effector immune cells such as microglia/macrophages undergo a  
343 metabolic reprogramming process<sup>5,7</sup>. Here, we have monitored this effect in primary  
344 microglia and its consequences in mitochondrial integrity; moreover, we have checked  
345 whether this metabolic switch is associated to mitochondrial fission. It is noteworthy to  
346 mention that the ablation of oxidative phosphorylation in active cells is not due to a  
347 challenge to mitochondrial integrity. Moreover, we have shown that Drp1-dependent  
348 mitochondrial fission, although potentially involved in microglial activation, does not  
349 play an essential role in metabolic reprogramming of microglia.

350 Upon pro-inflammatory stimulation, cells are able to redirect their entire metabolic  
351 processes to the glycolytic pathway, in order to rapidly obtain energy. This process is an  
352 outcome of different molecular pathways; nevertheless, the precise mechanisms involved  
353 are yet to be defined. Here, we have observed that even though the oxidative  
354 phosphorylation machinery is completely halted, this is not associated to mitochondrial  
355 damage or dysfunction nor with microglia cell death. This is opposed to what was  
356 observed when the Warburg effect was firstly described; he hypothesized that  
357 dysfunctional mitochondria would be the reason underlying the switch in metabolism and  
358 eventually, the development of cancer cells.<sup>38</sup> Indeed, recent studies have highlighted  
359 the importance of mitochondria regarding the production of ROS as agents to support not

360 only the development of cancer cells but also the pro-inflammatory state of macrophages  
361 <sup>39,40</sup>. Thus, toll like receptor activation in macrophages induced mitochondrial ROS  
362 generation, an essential step for efficient intracellular bacteria killing <sup>40</sup>. We observed that  
363  $\Delta\Psi_m$  was maintained in pro-inflammatory microglia through the reverse operation of  
364  $F_0F_1$ -ATP synthase and that this protects microglia from cell death. Indeed, the blockage  
365 of complex I, III and IV abolishes  $H^+$  translocation and it would lead to a transient drop  
366 in  $\Delta\Psi_m$ . However, the F1 subunit of  $F_0F_1$ -ATP synthase can hydrolyse mitochondrial  
367 ATP under these circumstances and drives the F0-rotor to pump  $H^+$  out of the matrix to  
368 be able to maintain the  $\Delta\Psi_m$  <sup>41</sup>. Thus, the mitochondria of pro-inflammatory microglia  
369 would become consumers, rather than ATP generators, further increasing the energetic  
370 demand of these cells <sup>42</sup>. We have not found any essential role in the ANT reversal  
371 activity, which has also been described as key in the  $\Delta\Psi_m$  maintenance process in similar  
372 paradigms <sup>32</sup>. Signalling events mediated by extracellular signals can regulate the  
373 metabolic pathways in immune cells, such as macrophages or microglia <sup>43</sup>. Accordingly,  
374 diverse cellular functions have been associated to metabolic reprogramming, including  
375 those related to mitochondrial function in general. Previous data suggested that  
376 mitochondrial dynamics contribute to this mechanism <sup>9</sup>. Our results demonstrated that  
377 Mdivi-1, a mitochondrial fission inhibitor a putative division inhibitor, reduced the  
378 enhancement of markers associated to microglial activation after LPS and IFN- $\gamma$   
379 exposure. This effect on microglial activation is in agreement with other studies, even in  
380 other paradigms of treatment <sup>9,34</sup>. Drp1-mediated mitochondrial fission has been  
381 associated to enhanced activation of both p38 and NF- $\kappa\beta$ , both mediators of signalling  
382 cascades leading to the expression of pro-inflammatory genes, in a paradigm of diabetic  
383 nephropathy <sup>44</sup>. Moreover, blocking Drp1-dephosphorylation with oleuropein reduced the  
384 production of pro-inflammatory factors in microglia as well <sup>45</sup>. In contrast, blockage of

385 mitochondrial fission with Mdivi-1 did not avoid the microglial metabolism switch to  
386 glycolysis upon LPS+ IFN- $\gamma$  exposure, nor did it provoke any effect in the control cells.  
387 We concluded that mitochondria fission does not contribute to the metabolic switch in  
388 microglia. This result is apparently at odd with previous results<sup>9</sup>. The contradiction may  
389 be explained in the basis of the different paradigm used; in this study, microglia is  
390 exposed to Mdivi-1 as a pre-treatment, before the stimulation with LPS.

391 Distinct arginine metabolism plays a key role in the metabolic plasticity of immune cells.  
392 Pro-inflammatory microglia convert arginine into NO through iNOS activity, increased in  
393 this phenotype<sup>14,46</sup>. It has been described that the upregulation of iNOS and the resulting  
394 generation of NO contributes to the impairment of mitochondrial respiration both in  
395 immune cells as well as in astrocytes<sup>47,48</sup>. Moreover, editing macrophage and microglia  
396 (re)polarization is emerging as a new therapeutic approach and iNOS have been described  
397 as a target. Thus, iNOS inhibition improve metabolic and phenotypic reprogramming to  
398 anti-inflammatory macrophages<sup>37</sup>. Despite that Mdivi-1 treatment consistently reduced  
399 iNOS expression in pro-inflammatory microglia as well as we did not detect any  
400 significant improvement on mitochondrial respiration. There are two possible  
401 interpretations. The complete blockage of iNOS activity and total abolishment of NO  
402 production, as observed with the iNOS inhibitor 1400W, could be required to prevent the  
403 metabolic switch<sup>49</sup>. In this sense, Mdivi-1 only partially reduced iNOS expression in pro-  
404 inflammatory microglia. Alternatively, signalling pathways controlling metabolic switch  
405 could differ from those regulating phenotypic and inflammatory expression. Indeed,  
406 iNOS inhibition does not affect phenotypic polarization of cells, nor the inflammatory  
407 cytokine secretion of macrophages<sup>37</sup>. Accordingly, the effect of Mdivi-1 on pro-  
408 inflammatory gene expression does not produce any change on metabolism. For instance,  
409 Mdivi-1 rapidly and reversibly attenuated complex I-dependent reverse electron transfer-

410 mediated reactive oxygen species (ROS) production by brain mitochondria oxidizing  
411 succinate<sup>20</sup>.

## 412 **CONCLUSIONS**

413 In summary, the present study sheds some light into the role of mitochondria in the  
414 metabolic reprogramming process in microglia. Pro-inflammatory stimuli dampen  
415 mitochondrial function without compromising their integrity and our results point to F<sub>0</sub>F<sub>1</sub>-  
416 ATP synthase as a key regulator of mitochondrial potential and cell viability maintenance  
417 in these conditions. However, we concluded that mitochondrial dynamics, fusion-fission,  
418 although potentially involved in pro-inflammatory gene expression, do not contribute to  
419 microglial glycolytic switch after pro-inflammatory stimulation.

## **ACKNOWLEDGEMENTS**

420 We kindly acknowledge the Microscopy Facilities of both the University of the Basque  
421 Country (UPV/EHU) and Achucarro Basque Center for Neuroscience for the technical  
422 support.

## **AUTHORS CONTRIBUTION**

423 MD contributed to the conception and design of the study, data interpretation and  
424 manuscript writing. AM contributed to the data acquisition and analysis, data  
425 interpretation and manuscript writing. AR assisted to the data acquisition and  
426 interpretation. MM and AS contributed the analysis of mitochondrial morphology. CM  
427 substantially contributed to the revision of the work. All authors contributed to the  
428 manuscript revision, read, and approved the submitted version.

## **FUNDING**

429 This work was supported by grants from Merck Serono (a business of Merck KGaA,  
430 Darmstadt, Germany); Spanish Ministry of Education and Science (SAF2016-75292-R);  
431 Spanish Ministry of Science and Innovation (PID2019-109724RB-I00), Basque  
432 Government (IT1203/19 and PI-2016-1-0016) and Centro de Investigación Biomédica en  
433 Red sobre Enfermedades Neurodegenerativas (CIBERNED; grant CB06/05/0076) to MD  
434 and CM. Also, it was supported by grants from Spanish Ministry of Science and  
435 Innovation with FEDER funds (RTI2018-099267-B- I00); Tatiana Foundation Project (P-  
436 048-FTPGB 201) and Basque Government (PIBA 2020\_1\_0030) to AS. AM and MM  
437 are predoctoral fellows of the Spanish Ministry of Education and Science and the  
438 University of the Basque Country EHU/UPV, respectively.

## **COMPETING INTERESTS STATEMENT**

439 The authors declare no competing interests.

440 **DATA AVAILABILITY**

441 The datasets generated during and/or analysed during the current study are available from  
442 the corresponding author on reasonable request.

443 **REFERENCES**

- 444 1. Davalos, D. *et al.* ATP mediates rapid microglial response to local brain injury in vivo.  
445 *Nat. Neurosci.* **8**, 752–758 (2005).
- 446 2. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly  
447 dynamic surveillants of brain parenchyma in vivo. *Science* **308**, 1314–1318 (2005).
- 448 3. Ransohoff, R. & El Khoury, J. Microglia in health and disease. *Cold Spring Harb*  
449 *Perspect Biol* **8** (2016).
- 450 4. Xue, J. *et al.* Transcriptome-Based Network Analysis Reveals a Spectrum Model of  
451 Human Macrophage Activation. *Immunity* **40**, 274–288 (2014).
- 452 5. Andrejeva, G. & Rathmell, J. C. Similarities and Distinctions of Cancer and Immune  
453 Metabolism in Inflammation and Tumors. *Cell Metab.* **26**, 49–70 (2017).
- 454 6. Stienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B. & Netea, M. G.  
455 Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during  
456 Innate Immune Responses. *Cell Metab.* **26**, 142–156 (2017).
- 457 7. Kelly, B. & O’Neill, L. A. J. Metabolic reprogramming in macrophages and dendritic  
458 cells in innate immunity. *Cell Res.* **25**, 771–784 (2015).
- 459 8. Lauro, C. & Limatola, C. Metabolic Reprogramming of Microglia in the Regulation of the  
460 Innate Inflammatory Response. *Front Immunol.* **11**:493 (2020)  
461 doi:10.3389/fimmu.2020.00493.
- 462 9. Nair, S. *et al.* Lipopolysaccharide-induced alteration of mitochondrial morphology  
463 induces a metabolic shift in microglia modulating the inflammatory response in vitro and  
464 in vivo. *Glia* **67**, 1047–1061 (2019).
- 465 10. Hu, Y. *et al.* mTOR-mediated metabolic reprogramming shapes distinct microglia  
466 functions in response to lipopolysaccharide and ATP. *Glia* **68** 1031-1045 (2020)
- 467 11. Holland, R. *et al.* Inflammatory microglia are glycolytic and iron retentive and typify the  
468 microglia in APP/PS1 mice. *Brain. Behav. Immun.* **68**, 183–196 (2018).
- 469 12. Van den Bossche, J., O’Neill, L. A. & Menon, D. Macrophage Immunometabolism:  
470 Where Are We (Going)? *Trends Immunol.* **38**, 395–406 (2017).
- 471 13. Bernier, L. P., York, E. M. & MacVicar, B. A. Immunometabolism in the Brain: How  
472 Metabolism Shapes Microglial Function. *Trends Neurosci.* **43**, 854-869 (2020).

- 473 14. Rath, M., Müller, I., Kropf, P., Closs, E. I. & Munder, M. Metabolism via arginase or  
474 nitric oxide synthase : two competing arginine pathways in macrophages. *Front*  
475 *Immunol.* **5**:532 (2014).
- 476 15. Westermann, B. Mitochondrial fusion and fission in cell life and death. *Nat. Rev. Mol.*  
477 *Cell. Biol.* **11**, 872–884 (2010).
- 478 16. Ishihara, N. *et al.* Mitochondrial fission factor Drp1 is essential for embryonic  
479 development and synapse formation in mice. *Nat. Cell Biol.* **11**, 958–966 (2009).
- 480 17. Knott, A. B., Perkins, G., Schwarzenbacher, R. & Bossy-Wetzel, E. Mitochondrial  
481 Fragmentation in Neurodegeneration. *Nat Rev Neurosci* **9**, 505–518 (2008).
- 482 18. Cho, D. H., Nakamura, T. & Lipton, S. A. Mitochondrial dynamics in cell death and  
483 neurodegeneration. *Cell. Mol. Life Sci.* **67**, 3435–3447 (2010).
- 484 19. Reddy, P. *et al.* Dynamin-Related Protein 1 and Mitochondrial Fragmentation in  
485 Neurodegenerative Diseases. *Brain Res. Rev* **67**, 103–118 (2011).
- 486 20. Smirnova, E., Griparic, L., Shurland, D. & Blik, A. M. Van Der. Dynamin-related  
487 Protein Drp1 Is Required for Mitochondrial Division in Mammalian Cells. *Mol. Biol.*  
488 *Cell* **12**, 2245–2256 (2001).
- 489 21. Fonseca, T. B., Sánchez-Guerrero, Á., Milosevic, I. & Raimundo, N. Mitochondrial  
490 fission requires DRP1 but not dynamins. *Nature* **570**, E34–E42 (2019).
- 491 22. Cassidy-stone, A. *et al.* Chemical inhibition of the mitochondrial division dynamin  
492 reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization.  
493 *Dev.Cell.* **14**, 193–204 (2008).
- 494 23. Domercq, M. *et al.* System xc- and Glutamate Transporter Inhibition Mediates  
495 Microglial Toxicity to Oligodendrocytes. *J. Immunol.* **178**, 6549–6556 (2007).
- 496 24. Domercq M, Sánchez-Gómez MV, Areso P. & Matute, C. Expression of glutamate  
497 transporters in rat optic nerve. *Eur J Neurosci* **11(7)**, 2226–36 (1999).
- 498 25. Domercq, M. *et al.* PET imaging with [18F]FSPG evidences the role of system xc- on  
499 brain inflammation following cerebral ischemia in rats. *Theranostics* **6**, 1753–1767  
500 (2016).
- 501 26. Vandesompele, J. *et al.* Accurate normalization of real-time quantitative RT-PCR data  
502 by geometric averaging of multiple internal control genes. *Genome Biol.* **3** (2002)  
503 doi:10.1186/gb-2002-3-7-research0034.

- 504 27. Freya, T. G. & Mannellab, C. A. The internal structure of mitochondria. *Trends*  
505 *Biochem. Sci.* **25**, 319-324 (2000).
- 506 28. Orihuela, R., McPherson, C. A. & Harry, G. J. Microglial M1/M2 polarization and  
507 metabolic states. *Br. J. Pharmacol.* **173**, 649–665 (2016).
- 508 29. Everts, B. *et al.* TLR-driven early glycolytic reprogramming via the kinases TBK1-IKK $\epsilon$   
509 supports the anabolic demands of dendritic cell activation. *Nat. Immunol.* **15**, 323–332  
510 (2014).
- 511 30. Corona, J. C. & Duchen, M. R. Mitochondrial bioenergetics assessed by functional  
512 fluorescence dyes. *Neuromethods* (2014) doi:10.1007/978-1-4939-1059-5\_7.
- 513 31. Brocard, J. B., Tassetto, M. & Reynolds, I. J. Quantitative evaluation of mitochondrial  
514 calcium content in rat cortical neurones following a glutamate stimulus. *J. Physiol.* **531**,  
515 793–805 (2001).
- 516 32. Chinopoulos, C. Mitochondrial consumption of cytosolic ATP: Not so fast. *FEBS Lett.*  
517 **585**, 1255–1259 (2011).
- 518 33. Henderson, P. J. & Lardy, H. A. Bongkrekeic acid. An inhibitor of the adenine nucleotide  
519 translocase of mitochondria. *J. Biol. Chem.* **245**, 1319-1326 (1970).
- 520 34. Katoh, M. *et al.* Polymorphic regulation of mitochondrial fission and fusion modifies  
521 phenotypes of microglia in neuroinflammation. *Sci. Rep.* **7** (2017).
- 522 35. Bordt, E. A. *et al.* The Putative Drp1 Inhibitor mdivi-1 Is a Reversible Mitochondrial  
523 Complex I Inhibitor that Modulates Reactive Oxygen Species. *Dev. Cell* **40**, 583-594.e6  
524 (2017).
- 525 36. Fumagalli, M., Lombardi, M., Gressens, P. & Verderio, C. How to reprogram microglia  
526 toward beneficial functions. *Glia* **66**, 2531–2549 (2018).
- 527 37. Van den Bossche, J. *et al.* Mitochondrial Dysfunction Prevents Repolarization of  
528 Inflammatory Macrophages. *Cell Rep.* **17**, 684–696 (2016).
- 529 38. Warburg, O. On the origin of cancer cells. *Science* **123**, 309–314 (1956).
- 530 39. Porporato, P. E., Filigheddu, N., Pedro, J. M. B. S., Kroemer, G. & Galluzzi, L.  
531 Mitochondrial metabolism and cancer. *Cell Res.* **28**, 265–280 (2018).
- 532 40. West, A. P. *et al.* TLR signalling augments macrophage bactericidal activity through  
533 mitochondrial ROS. *Nature* **472**, 476–480 (2011).
- 534 41. Kinoshita, K., Adachi, K. & Itoh, H. Rotation of F1-ATPase: How an ATP-driven


- 535 molecular machine may work. *Annu. Rev. Biophys. Biomol. Struct.* **33**, 245–268 (2004).
- 536 42. Solaini, G., Baracca, A., Lenaz, G. & Sgarbi, G. Hypoxia and mitochondrial oxidative  
537 metabolism. *Biochim. Biophys. Acta - Bioenerg.* **1797**, 1171–1177 (2010).
- 538 43. Wang, S. *et al.* Metabolic reprogramming of macrophages during infections and cancer.  
539 *Cancer Lett.* **452**, 14–22 (2019).
- 540 44. Zhang, L. *et al.* Inhibition to DRP1 translocation can mitigate p38 MAPK-signaling  
541 pathway activation in GMC induced by hyperglycemia. *Ren. Fail.* **37**, 903–910 (2015).
- 542 45. Park, J. *et al.* Anti-inflammatory effect of oleuropein on microglia through regulation of  
543 Drp1-dependent mitochondrial fission. *J. Neuroimmunol.* **306**, 46–52 (2017).
- 544 46. Yang, Z. & Ming, X. F. Functions of arginase isoforms in macrophage inflammatory  
545 responses: Impact on cardiovascular diseases and metabolic disorders. *Front. Immunol.* **5**  
546 (2014).
- 547 47. Everts, B. *et al.* Commitment to glycolysis sustains survival of NO-producing  
548 inflammatory dendritic cells. *Blood* **120**, 1422–1431 (2012).
- 549 48. Bolaños, J. P., Peuchen, S., Heales, S. J. R., Land, J. M. & Clark, J. B. Nitric Oxide-  
550 Mediated Inhibition of the Mitochondrial Respiratory Chain in Cultured Astrocytes. *J.*  
551 *Neurochem.* **63**, 910–916 (1994).
- 552 49. Garvey, E. P. *et al.* 1400W is a slow, tight binding, and highly selective inhibitor of  
553 inducible nitric-oxide synthase in vitro and in vivo. *J. Biol. Chem.* **272**, (1997).

**Table 1**

<b>Target gene</b>	<b>Forward sequence (5'-&gt;3')</b>	<b>Reverse sequence (5'-&gt;3')</b>
<b>Arg1</b>	GGATTGGCAAGGTGATGGAA	CGACATCAAAGCTCAGGTGAA
<b>Ccl2</b>	AGCAGCAGGTGTCCCAA	TTCTTGGGGTCAGCACAGAC
<b>Il1b</b>	TGGCAACTGTTCTGAACTCA	GGGTCCGTCAACTTCAAAGAAC
<b>Nos2</b>	GAGGAGCAGGTGGAAGACTA	GGAAAAGACTGCACCGAAGATA
<b>Housekeeping gene</b>	<b>Forward sequence (5'-&gt;3')</b>	<b>Reverse sequence (5'-&gt;3')</b>
<b>Hprt2</b>	CAGTACAGCCCCAAAATGGTTA	AGTCTGGCCTGTATCCAACA
<b>Ppia</b>	AGGGTTCCTCCTTTCACAGAA	TGCCGCCAGTGCCATTA

555 **Table 1. List of primers for quantitative real-time PCR.** Primers were designed using Primer  
556 Express software (Applied Biosystems) at exon junctions to avoid genomic DNA amplification

557 **FIGURES**



558 **Figure 1. Robust metabolic reprogramming to glycolytic pathway after 24 hours of**  
 559 **pro-inflammatory stimulation in microglia**

560 (A) Representative experiment of OCR measurements in control microglia and in microglia  
 561 after 24 hours of pro-inflammatory (LPS + IFN $\gamma$ ) and anti-inflammatory (IL-4 + IL-13)  
 562 stimulations. Histograms show metabolic parameters obtained by the analysis of this  
 563 metabolic profile compared to control cells (n = 7 independent experiments).

564 (B) ECAR measurement obtained by the secretion of lactate of control microglia and  
 565 microglia after 24-hour incubation with pro- and anti-inflammatory factors (n = 7).  
 566 Histograms show the basal level of this parameter as well as the increase provoked by the  
 567 acute treatment with oligomycin, relative to the control cells. Statistical analysis was  
 568 performed by one-way ANOVA followed by Bonferroni post-hoc test.


569 (C) Ratio between the basal OCR and the basal glycoPER control and both pro-inflammatory  
 570 and anti-inflammatory microglia after 24 hours of stimulation. These parameters were  
 571 obtained using the XF Glycolytic Rate Assay test (n = 3 independent experiments).

572 (D) Metabolic profile of microglia after acute treatment with LPS and IFN $\gamma$  (n = 3)

573 (E) Metabolic profile of microglia treated during different time lapses with LPS and IFN $\gamma$ .

574 Histograms shows the metabolic parameters compared to control cells (n = 3).

575 Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.001. Unless otherwise  
 576 stated, Student's t-test was used to analyse the data.



578

579 **Figure 2. Pro-inflammatory microglia maintain mitochondrial integrity upon**  
 580 **ATPase activity blockade**

581 (A) Measurement of mitochondrial potential, represented as the increase in cytoplasmic  
582 Rh123 fluorescence measured after acute exposure to FCCP in control and LPS+IFN $\gamma$   
583 treated microglia (n = 50-75 cells from three independent experiments).

584 (B) Measurement of mitochondrial-specific calcium represented as the increase in  
585 cytoplasmic Fluo-4 fluorescence in a Ca<sup>2+</sup>-free medium, after exposure to FCCP, in  
586 control and LPS+IFN $\gamma$  treated cells (n = 50-75 cells from three independent experiments).

587 (C) Reactive oxygen species quantification in control and pro-inflammatory cells (n = 3  
588 experiments performed in triplicate).


589 (D) Microglial viability after 24-hour treatment with LPS+IFN $\gamma$ , oligomycin and/or  
590 bongkreikic acid, compared to control cells. One-way ANOVA followed by Bonferroni  
591 post-hoc analysis (n = 3 experiments performed in triplicate).

592 (E) Effect of ATPase inhibitor oligomycin in mitochondrial potential of control and  
593 LPS+IFN- $\gamma$  treated cells (n = 70-80 cells from three independent experiments).

594 Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.001. Unless otherwise  
595 stated, Student's t-test was used to analyze the data.

596

597



598


599 **Figure 3. Mitochondrial fission inhibition reduces the microglial inflammatory**  
 600 **markers**

- 601 (A) Representative images of Iba1<sup>+</sup> control and Mdivi-1 treated microglia. Right column  
602 shows Iba1<sup>+</sup> and DAPI staining (merge). Scale bar = 25  $\mu$ m. Histogram represents the  
603 circularity of the cells as calculated by ImageJ software (n = 200 cells from three  
604 independent experiments).
- 605 (B) Expression of anti-inflammatory (MNR) and pro-inflammatory mediators (iNOS) in  
606 control and Mdivi-1 treated microglia (n = 4 independent experiments performed with  
607 duplicates).
- 608 (C) Microglial viability in control and Mdivi-1 cells, measured by both calcein assay and the  
609 quantification of LDH release to the medium, indicative of cell death (n = 3 experiments  
610 performed in triplicate).
- 611 (D) Representative immunostaining of MNR and iNOS in control microglia, as well as in  
612 cells treated with LPS+IFN $\gamma$  or Mdivi-1 and LPS+IFN $\gamma$ . Scale bar = 40  $\mu$ m. Histograms  
613 represent the mean fluorescence of the staining per cell (n = 4 independent experiments  
614 performed with duplicates). One-way ANOVA followed by Bonferroni post-hoc  
615 analysis.
- 616 (E) Quantitative real time PCR (qRT-PCR) of pro-inflammatory (left) and an anti-  
617 inflammatory mediators (right) in control microglia, as well as in microglia treated with  
618 Mdivi-1, LPS+IFN $\gamma$ , and Mdivi-1 + LPS+IFN $\gamma$  (n = 4 experiments performed in  
619 duplicate). Data are expressed relative to the expression in LPS+IFN $\gamma$ . One-way ANOVA  
620 followed by Bonferroni post-hoc analysis.

621 Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.001. Unless otherwise  
622 stated, Student's t-test was used to analyze the data.

623

624




625

626 **Figure 4. Mitochondrial fission inhibition does not reverse mitochondrial metabolic**  
 627 **reprogramming**

628 (A) Metabolic profile of control and microglia treated for 1 hour with Mdivi-1 (above).  
 629 Histogram shows the metabolic parameters related to OCR of Mdivi-1 treated cells,  
 630 compared to the control ones (n = 3).

631 (B) Metabolic profile of control microglia, as well as microglia treated for 24 hours with  
 632 Mdivi-1, LPS+IFN $\gamma$  and Mdivi-1 + LPS+IFN $\gamma$ . Histograms show the metabolic  
 633 parameters related to OCR compared to control microglia (n = 3).

634 Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*\*p < 0.001. One-way ANOVA followed by  
 635 Bonferroni post-hoc analysis.



636 **Figure 5. Mdivi-1 treatment does not promote microglial repolarization**


637 (A) Scheme of the conditions used to study the role of Mdivi-1 in the repolarization capacity  
 638 of microglia. Each treatment indicated lasts 24 hours. Anti-inflammatory microglia (ILs-  
 639 treated) were compared to microglia that were primed for 24 hr with LPS + IFN $\gamma$  before  
 640 24 hr treatment with ILs.

641 (B) Expression of anti-inflammatory (MRC1) and pro-inflammatory (iNOS) markers in every  
 642 condition of the repolarization experiment. Histograms represent the mean  $\pm$  s.e.m of the  
 643 marker fluorescence intensity per cell (n =3 experiments performed in triplicate).

644 (C) Metabolic profile (left) of microglia treated as schematized in subfigure A. Histograms  
 645 (right) show metabolic parameters regarding OCR of the cells (n =3). Data was expressed  
 646 as fold change versus control non-treated microglia.


647 Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.001. Student's t-test.

# Figures



**Figure 1**


Robust metabolic reprogramming to glycolytic pathway after 24 hours of pro-inflammatory stimulation in microglia (A) Representative experiment of OCR measurements in control microglia and in microglia after 24 hours of pro-inflammatory (LPS + IFN $\gamma$ ) and anti-inflammatory (IL-4 + IL-13) stimulations. Histograms show metabolic parameters obtained by the analysis of this metabolic profile compared to control cells (n = 7 independent experiments). (B) ECAR measurement obtained by the secretion of lactate of control microglia and microglia after 24-hour incubation with pro- and anti-inflammatory factors (n = 7). Histograms show the basal level of this parameter as well as the increase provoked by the acute treatment with oligomycin, relative to the control cells. Statistical analysis was performed by one-way ANOVA followed by Bonferroni post-hoc test. (C) Ratio between the basal OCR and the basal glycoPER control and both pro-inflammatory and anti-inflammatory microglia after 24 hours of stimulation. These parameters were obtained using the XF Glycolytic Rate Assay test (n = 3 independent experiments). (D) Metabolic profile of microglia after acute treatment with LPS and IFN $\gamma$  (n = 3) (E) Metabolic profile of microglia treated during different time lapses with LPS and IFN $\gamma$ . Histograms shows the metabolic parameters compared to control cells (n = 3). Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.001. Unless otherwise stated, Student's t-test was used to analyse the data.



**Figure 2**

Pro-inflammatory microglia maintain mitochondrial integrity upon ATPase activity blockade (A) Measurement of mitochondrial potential, represented as the increase in cytoplasmic Rh123 fluorescence measured after acute exposure to FCCP in control and LPS+IFN $\gamma$  treated microglia (n = 50-75 cells from three independent experiments). (B) Measurement of mitochondrial-specific calcium represented as the increase in cytoplasmic Fluo-4 fluorescence in a Ca<sup>2+</sup>-free medium, after exposure to FCCP, in control and LPS+IFN $\gamma$  treated cells (n = 50-75 cells from three independent experiments). (C) Reactive oxygen species quantification in control and pro-inflammatory cells (n = 3 experiments performed in triplicate). (D) Microglial viability after 24-hour treatment with LPS+IFN $\gamma$ , oligomycin and/or bongkreikic acid, compared


to control cells. One-way ANOVA followed by Bonferroni post-hoc analysis ( $n = 3$  experiments performed in triplicate). (E) Effect of ATPase inhibitor oligomycin in mitochondrial potential of control and LPS+IFN $\gamma$  treated cells ( $n = 70$ -80 cells from three independent experiments). Data are presented as means  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.001$ . Unless otherwise stated, Student's t-test was used to analyze the data.



**Figure 3**


Mitochondrial fission inhibition reduces the microglial inflammatory markers (A) Representative images of Iba1+ control and Mdivi-1 treated microglia. Right column shows Iba1+ and DAPI staining (merge). Scale bar = 25  $\mu$ m. Histogram represents the circularity of the cells as calculated by ImageJ software ( $n = 200$  cells from three independent experiments). (B) Expression of anti-inflammatory (MNR) and pro-

inflammatory mediators (iNOS) in control and Mdivi-1 treated microglia (n = 4 independent experiments performed with duplicates). (C) Microglial viability in control and Mdivi-1 cells, measured by both calcein assay and the quantification of LDH release to the medium, indicative of cell death (n = 3 experiments performed in triplicate). (D) Representative immunostaining of MNR and iNOS in control microglia, as well as in cells treated with LPS+IFN $\gamma$  or Mdivi-1 and LPS+IFN $\gamma$ . Scale bar = 40  $\mu$ m. Histograms represent the mean fluorescence of the staining per cell (n = 4 independent experiments performed with duplicates). One-way ANOVA followed by Bonferroni post-hoc analysis. (E) Quantitative real time PCR (qRT-PCR) of pro-inflammatory (left) and an anti-inflammatory mediators (right) in control microglia, as well as in microglia treated with Mdivi-1, LPS+IFN $\gamma$ , and Mdivi-1 + LPS+IFN $\gamma$  (n = 4 experiments performed in duplicate). Data are expressed relative to the expression in LPS+IFN $\gamma$ . One-way ANOVA followed by Bonferroni post-hoc analysis. Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.001. Unless otherwise stated, Student's t-test was used to analyze the data.



**Figure 4**

Mitochondrial fission inhibition does not reverse mitochondrial metabolic reprogramming (A) Metabolic profile of control and microglia treated for 1 hour with Mdivi-1 (above). Histogram shows the metabolic parameters related to OCR of Mdivi-1 treated cells, compared to the control ones (n = 3). (B) Metabolic profile of control microglia, as well as microglia treated for 24 hours with Mdivi-1, LPS+IFN $\gamma$  and Mdivi-1 + LPS+IFN $\gamma$ . Histograms show the metabolic parameters related to OCR compared to control microglia (n = 3). Data are presented as means  $\pm$  SEM. \*p < 0.05, \*\*\*p < 0.001. One-way ANOVA followed by Bonferroni post-hoc analysis.



**Figure 5**

Mdivi-1 treatment does not promote microglial repolarization (A) Scheme of the conditions used to study the role of Mdivi-1 in the repolarization capacity of microglia. Each treatment indicated lasts 24 hours. Anti-inflammatory microglia (ILs- treated) were compared to microglia that were primed for 24 hr with LPS + IFN $\gamma$  before 24 hr treatment with ILs. (B) Expression of anti-inflammatory (MRC1) and pro-inflammatory (iNOS) markers in every condition of the repolarization experiment. Histograms represent the mean  $\pm$  s.e.m of the marker fluorescence intensity per cell (n =3 experiments performed in triplicate). (C) Metabolic profile (left) of microglia treated as schematized in subfigure A. Histograms (right) show metabolic parameters regarding OCR of the cells (n =3). Data was expressed as fold change versus control non-treated microglia. Data are presented as means  $\pm$  SEM. \* $p$  < 0.05, \*\* $p$  < 0.005, \*\*\* $p$  < 0.001. Student's t-test.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarymaterial.docx](#)